\
&
Contact us
This was 4 years ago
LocationOnline
ProgrammesGetting ready for the opening of the calls for 2021 also implies finding (potential) partners. To facilitate this, you can participate in a brokerage event with pre-arranged online Face2Face meetings. This brokerage event complements the official and EC-organised Cluster 4 Info Day.
In this context the network of Space National Contact Points, COSMOS2020plus with support of the Enterprise Europe Network (EEN), is organising a free of charge online Space Brokerage Event on 28 June 2021. The event will give participants the opportunity to matchmake with others through pre-arranged meetings in order to identify possible collaborations and business cases and to facilitate the setup of Horizon Europe project consortia. For this, registrants will enter profiles including search terms comprising the Space call titles of 2021 and 2022 (Space calls from both years are foreseen to be opened in parallel in October 2021, please see the topics here).
Who should participate?
Why participate?
Participation in this matchmaking event is free of charge. Registration is mandatory.
More information and how to register can be found via this link: https://cosmos2020plus-heu-cluster4-space-brokerage.b2match.io/
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.